Crossmark

Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy

Crossref DOI link: https://doi.org/10.1038/s41409-021-01327-5

Published Online: 2021-05-13

Published Print: 2021-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Vijenthira, Abi

Kuruvilla, John

Prica, Anca https://orcid.org/0000-0001-5621-9261
Funding

Funding for this research was provided by:

University of Toronto Postgraduate Medicine Research Award
License Information

Text and Data Mining valid from 2021-05-13

Version of Record valid from 2021-05-13
More Information

Article History

Received: 17 December 2020

Revised: 16 April 2021

Accepted: 22 April 2021

First Online: 13 May 2021

Compliance with ethical standards

:

: AV: No relevant disclosures; JK: BMS: Consultancy, Honoraria; Abbvie: Consultancy; Leukemia and Lymphoma Society Canada: Research Funding; Seattle Genetics: Consultancy, Honoraria; Amgen: Honoraria; Celgene: Honoraria; Karyopharm: Honoraria; Janssen: Consultancy, Honoraria, Research Funding; Princess Margaret Cancer Foundation: Research Funding; Gilead: Consultancy, Honoraria; Lundbeck: Honoraria; Roche: Consultancy, Honoraria, Research Funding; Merck: Consultancy, Honoraria; AP: Astra Zeneca: Honoraria, Advisory Board; Gilead: Honoraria, Advisory Board.

Document is current

Any future updates will be listed below